OakChart

Eocene Ltd

EOCNHealthcare·Biotechnology·Israel·Nano·NASD·Nov 12 • 3:58 PM ET

2.39-0.09 (-3.63%)
2026-11-13 05:22 CET
Market cap
$2.49M
Revenue, TTM
0.00 USD m
Net income, TTM
-11.34 USD m
Free cash flow, TTM
-8.54 USD m
EPS diluted, TTM
-13.81
Price / earnings
-
Compare

Price

EOCN against its 20, 50 and 200-day averages
Terms2050200Beat
Patternshover a marker to name it
EPS mean, own scale
RS 0EPS -3.06Price-3.122.004.006.008.001.4M2.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EOCNclose 2.3920-day 2.8850-day 3.30200-day 4.422.3952w low

80.6% under the 52-week high of 12.32 on 17 Nov 2025. 52-week low 2.05 on 11 Nov 2026. Last 15 sessions, 69.7% high to low

Volume 0.14× normal · the line is the 50-bar volume average

Setup. RS line 0
CANSLIM 1 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K — not on the tape: EPS Growth This Year: High (>25%)
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — fails: Return on Equity: Over +15% — not on the tape: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%)
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K

Profile

EOCN
52-week range, 3% of the way up
2.0512.32

Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Employees6
IPOMar 13, 2014
Beta0.72
ATR, 14d0.33
Rel volume0.14
Short float0.82%
Insider own2.43%
Inst own3.95%

Snapshot

6 groups

Valuation

Index-
Market Cap$2.49M
Enterprise Value-8.77M
Income-11.34M
Sales0.00M
Book / share12.72
Cash / share10.95
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees6
IPOMar 13, 2014

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales-
Price / book0.19
Price / cash0.22
Price / free cash flow-
Value / cash profit-
Value / sales-
Quick Ratio4.16
Current Ratio4.16
Debt / equity0.01
Long-term debt / equity0.00
Options and shortNo / Yes

Earnings

Earnings / share-13.81
Earnings next year-
Earnings next quarter-
Earnings this year-
Earnings next year-
Earnings growth, 5 years-
Past earnings growth73.46% 60.33%
Past sales growth- -
Earnings vs last year68.55%
Sales vs last year-
Earnings vs last quarter43.43%
Sales vs last quarter-
EarningsJul 30
Surprise8.33% -

Ownership

Insiders own2.43%
Insider trades0.00%
Institutions own3.95%
Institution trades0.25%
Return on assets-55.03%
Return on equity-68.21%
Return on capital-88.73%
Gross Margin-
Operating margin-
Profit Margin-
20-day average-17.16%
50-day average-27.61%
200-day average-45.88%

Technical

Shares out1.04M
Shares floating1.02M
Short / float0.82%
Short ratio0.34
Short interest0.01M
52-week high12.32 -80.6%
52-week low2.05 +16.6%
Volatility15.78% 11.57%
Average range0.33
Strength index31.95
Market sensitivity0.72
Relative volume0.14
Avg Volume24.93K
Volume3,434

Performance

Perf Week-2.45%
Perf Month-20.60%
Perf Quarter-42.89%
Perf Half Y-54.63%
Perf YTD-60.19%
Perf Year-74.02%
Perf 3Y-93.43%
Perf 5Y-99.94%
Perf 10Y-99.95%
Recommendation1.00
Target Price96.00
Prev Close2.48
Price2.39
Change %-3.63%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
May 22, 2020DowngradeB. Riley FBRBuy → Neutral$11 → $8+234.7%
Feb 04, 2020InitiatedCraig HallumBuy$18+653.1%
Jan 30, 2020ResumedCantor FitzgeraldOverweight$9 → $14+485.8%
Dec 02, 2019InitiatedCanaccord GenuityBuy
Dec 12, 2018InitiatedB. Riley FBRBuy$28+1,071.5%
Aug 02, 2018ReiteratedMaxim GroupBuy$30 → $27+1,029.7%
Jul 13, 2018InitiatedStifelBuy$35+1,364.4%
Jul 12, 2018InitiatedCantor FitzgeraldOverweight$59+2,368.6%
Jun 12, 2018ReiteratedH.C. WainwrightBuy$24 → $43+1,699.2%
Mar 15, 2018UpgradeMaxim GroupHold → Buy$14+485.8%

Peers

Mkt cap
TickerCompanyMkt cap
CLDICalidi Biotherapeutics Inc2.41M
CVKDCadrenal Therapeutics Inc5.38M
HCWBHCW Biologics Inc1.79M
MBIOMustang Bio Inc3.52M
SXTP60 Degrees Pharmaceuticals Inc1.83M
MDGLMadrigal Pharmaceuticals Inc9.88B
SKYESkye Bioscience Inc4.78M
ALTAltimmune Inc313.17M
VKTXViking Therapeutics Inc3.52B
LXRXLexicon Pharmaceuticals Inc810.33M

News

latest 14 of 200
  • Eocene Announces its First European Sales and Distribution Agreement to Accelerate the Commercialization of Colospan's CG-100 Device (PR Newswire)
  • Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation (PR Newswire) +21.05%
  • Galmed Pharmaceuticals: Q2 Earnings Snapshot (Associated Press)
  • Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology (PR Newswire) +6.44%
  • Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI) Alone in Prostate Cancer Models (PR Newswire)
  • Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market (PR Newswire)
  • Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD) (InvestorsHub) +7.13%
  • Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol (PR Newswire)
  • Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition (PR Newswire)
  • Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market (PR Newswire) -32.57%
  • Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis (PR Newswire)
  • Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg (PR Newswire) +10.62%
  • Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics (PR Newswire) +6.41%
  • Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers (PR Newswire) -6.70%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-07-30-2.860-3.120-2.8600.00-1
2026Q12026-05-20-3.040-3.040-2.3181.64-1
2025Q42026-04-01-6.400--5.8571.64--
2025Q32025-11-26-2.640-4.320-2.7721.64-1
2025Q22025-08-28-5.040--5.0561.64--
2025Q12025-05-22-4.960-7.120-4.9631.541.541
2024Q42025-03-26-15.520--15.4201.64--
2023Q32023-11-06-25.920-28.800-22.6390.00-1
2023Q22023-08-09-32.640-32.640-91.0160.000.001
2023Q12023-06-01-104.64-144-104.560.00-1
2022Q42023-03-29-144-201.6-150.780.000.001
2022Q32022-11-16-295.2-237.6-305.840.000.004
2022Q22022-08-04-216-334.08-214.320.000.005
2022Q12022-05-17-345.6-452.16-352.580.000.005
2021Q42022-05-02-432-345.6-427.720.000.001
2021Q32021-11-08-446.4-504-442.840.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-777.6-711-782.52.042.17
2019FY-1,397-1,355-1,3950.000.00
2020FY-1,944-1,795-1,9470.000.00
2021FY-1,901-1,872-1,9010.00-
2022FY-1,022--1,0230.00-
2024FY-73.440--64.6056.28-
2025FY-19.120--19.1206.28-
2026FY--11.410--0.00
2027FY--2.170--0.19
2028FY--2.070--1.71
2029FY--1.550--5.64
2030FY--1.200--8.33

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-091000.000.000.00
2026Q3R2026-09-09110-3.06-3.06-3.06
2026Q3R2026-05-20100-3.12-3.12-3.12
2026Q3R2026-04-14100-3.12-3.12-3.12
2026Q3E2026-09-09110-3.06-3.06-3.06
2026Q3E2026-05-20100-3.12-3.12-3.12
2026Q3E2026-04-14100-3.12-3.12-3.12
2026Q2R2026-05-20100-0.39-0.39-0.39
2026Q2R2026-04-14100-0.39-0.39-0.39
2026Q2E2026-05-20100-0.39-0.39-0.39
2026Q2E2026-04-14100-0.39-0.39-0.39
2026Q1R2026-04-14100-3.04-3.04-3.04
2026Q1E2026-04-14100-3.04-3.04-3.04
2026FYS2026-09-091000.000.000.00

Estimate history

EPS, annual-1411.2-782.496-1395.432-1946.837-1900.685-1023.235-239.589-64.605-19.129-13.8063
Period201720182019202020212022202320242025TTM
EPS, quarterly-17.066-18.459-15.42-4.963-5.056-2.772-5.857-2.318-2.86
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual1.0852.03800000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.010.0150.0150.0150.0170.0180.0530.2080.8231.001
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0660.1880.2080.2820.6630.6850.8230.8251.001
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.002.04
Cost of Goods Sold Incl. D&A0.000.000.080.030.040.040.040.04-
Gross Profit0.000.00-0.08-0.03-0.04-0.04-0.04-0.04-
Selling, General and Administrative Excl. Other9.968.516.207.4617.6232.8430.1722.3412.37
Research and Development6.324.872.983.5712.9927.2226.0818.188.31
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-9.96-8.51-6.28-7.49-17.65-32.88-30.21-22.38-10.71
Interest Expense-0.020.010.010.020.040.030.030.00
Unusual Expense1.942.461.15-0.27-0.000.00--
Net Income Before Taxes-11.34-10.31-7.52-6.91-17.87-32.47-28.77-20.46-9.78
Income Taxes0.000.000.000.000.000.000.000.000.07
Consolidated Net Income-11.34-10.31-7.52-6.91-17.87-32.47-28.77-20.46-9.86
Net Income From Continuing Operations-11.34-10.31-7.52-6.91-17.87-32.47-28.77-20.46-9.86
Net Income-11.34-10.31-7.52-6.91-17.87-32.47-28.77-20.46-9.86
EPS (Recurring)-10.49-15.93-57.72-246.02-1,023.24-1,900.69-1,946.84-1,395.44-782.49
EPS (Basic, Before Extraordinaries)-13.81-19.13-64.61-239.59-1,023.24-1,900.68-1,946.84-1,395.43-782.50
EPS (Diluted)-13.81-19.13-64.61-239.59-1,023.24-1,900.68-1,946.84-1,395.43-782.50
EBITDA--8.51-6.20-7.46-17.62-32.84-30.17-22.34-10.33
Non-Operating Income (Expense)0.650.68-0.080.33-0.190.461.471.950.93
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.660.550.530.891.301.892.062.231.41
Price To Sales Ratio--------60.79
Operating Margin---------525.76
Net Margin---------483.61
Shares Outstanding1.000.820.210.050.020.020.010.010.01
Market Capitalization2.492.495.311.8212.6045.6666.32122.19143.56

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other2.772.043.042.102.111.261.642.01
Research and Development1.781.362.101.091.060.631.070.74
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.77-2.04-3.04-2.10-2.11-1.26-1.64-2.01
Interest Expense0.100.00-0.000.000.00-0.00
Unusual Expense0.000.001.940.000.530.001.150.00
Net Income Before Taxes-2.72-1.91-4.82-1.89-2.50-1.10-3.21-1.91
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.72-1.91-4.82-1.89-2.50-1.10-3.21-1.91
Net Income From Continuing Operations-2.72-1.91-4.82-1.89-2.50-1.10-3.21-1.91
Net Income-2.72-1.91-4.82-1.89-2.50-1.10-3.21-1.91
EPS (Recurring)-2.86-2.32-4.21-2.77-4.31-4.96-11.57-18.46
EPS (Basic, Before Extraordinaries)-2.86-2.32-5.86-2.77-5.06-4.96-15.42-18.46
EPS (Diluted)-2.86-2.32-5.86-2.77-5.06-4.96-15.42-18.46
EBITDA--2.04-3.04-2.10-2.11-1.26-1.64-2.01
Non-Operating Income (Expense)0.150.130.160.200.140.16-0.420.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.160.160.240.100.100.100.120.13
Shares Outstanding1.000.820.820.680.660.280.210.19
Market Capitalization2.493.234.947.569.763.255.3110.34

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments18.2815.4512.7613.9034.9351.0075.6090.1919.00
Short Term Receivables0.080.210.170.120.080.070.230.220.15
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.270.460.320.701.050.750.600.000.00
Total Current Assets18.6316.1213.2414.7236.0551.8176.4390.4119.15
Net Property, Plant & Equipment0.000.000.120.340.550.570.710.190.49
Total Investments and Advances0.002.383.271.500.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets18.6318.5016.6316.5636.6052.3877.1490.6019.64
Short Term Debt Incl. Current Port. of LT Debt0.000.000.040.000.000.000.000.000.00
Accounts Payable2.001.311.882.564.877.056.001.812.28
Other Current Liabilities0.840.860.830.531.010.970.940.891.57
Total Current Liabilities2.852.172.753.095.888.016.932.713.85
Long Term Debt0.000.000.000.040.230.220.350.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities2.852.172.753.146.118.237.292.713.85
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity15.7816.3313.8813.4230.5044.1569.8587.8915.79
Total Shareholders Equity15.7816.3313.8813.4230.5044.1569.8587.8915.79
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity15.7816.3313.8813.4230.5044.1569.8587.8915.79
Total Liabilities & Stockholders Equity18.6318.5016.6316.5636.6052.3877.1490.6019.64
Book Value Per Share19.1878.45264.08766.931,750.442,981.364,758.346,021.591,575.65
Tangible Book Value Per Share19.1878.45264.08766.931,750.442,981.364,758.346,021.591,575.65
Full-Time Employees668202424212117
Price to Book Ratio0.190.330.120.801.501.501.751.6317.84
Return on Assets-55.53-42.80-41.65-67.21-72.97-44.43-24.40-17.88-68.15
Return on Equity-64.21-49.77-50.63-81.36-86.98-50.47-25.94-19.01-91.54
Return on Invested Capital-65.32-46.04-49.80-132.67-105.67-64.84-29.14-11.21-77.87
Quick Ratio6.557.424.814.766.136.4711.0233.414.98
Current Ratio6.557.424.814.766.136.4711.0233.414.98

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-11.34-10.31-7.52-6.91-17.87-32.47-28.77-20.46-9.86
Depreciation-0.000.080.030.040.040.040.040.39
Other Funds (Non Cash)3.043.082.280.611.781.981.342.051.65
Funds from Operations-8.30-7.23-5.15-6.27-16.05-30.44-27.39-18.37-7.82
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.240.91-0.730.13-2.45-2.451.103.44-1.21
Cash from Operating Activities-8.54-6.32-5.88-6.14-18.50-32.89-26.29-14.94-9.02
Capital Expenditures0.000.000.000.00-0.00-0.01-0.04-0.01-0.09
Net Assets From Acquisitions-3.180.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments7.00-3.38-1.110.8017.5711.4716.586.69-59.92
Purchase of Investments-0.97-4.99-6.62-7.83-3.87-13.57-55.03-94.41-98.35
Sale Or Maturity of Investments7.971.615.508.6321.4425.0471.61101.1038.42
Other Uses0.000.000.000.000.00-0.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities3.82-3.38-1.110.8017.5611.4616.546.68-60.02
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock2.689.038.796.180.0717.370.770.1480.18
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock2.689.038.796.180.0717.370.770.1480.18
Proceedsfrom Stock Options2.689.034.396.180.0717.370.710.0079.15
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities2.689.038.796.180.0717.370.770.1480.18
Net Change in Cash-2.04-0.661.790.85-0.87-4.06-8.98-8.1211.14
Free Cash Flow-8.54-6.32-5.88-6.14-18.50-32.90-26.33-14.95-9.11
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments11.3915.5818.2819.1820.6515.85
Short Term Receivables0.320.450.080.550.430.45
Inventories0.000.000.000.000.000.00
Other Current Assets0.000.000.270.000.000.00
Total Current Assets11.7116.0318.6319.7221.0816.30
Net Property, Plant & Equipment0.160.000.000.000.000.00
Total Investments and Advances0.000.000.001.861.862.39
Intangible Assets6.410.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets18.2816.0318.6321.5822.9418.68
Short Term Debt Incl. Current Port. of LT Debt0.080.000.000.000.000.00
Accounts Payable1.901.722.001.671.371.31
Other Current Liabilities0.830.350.840.801.050.50
Total Current Liabilities2.812.082.852.472.421.81
Long Term Debt0.050.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities1.07-----
Other Liabilities1.620.000.000.000.000.00
Total Liabilities5.542.082.852.472.421.81
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity12.7413.9515.7819.1120.5216.88
Total Shareholders Equity12.7413.9515.7819.1120.5216.88
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity12.7413.9515.7819.1120.5216.88
Total Liabilities & Stockholders Equity18.2816.0318.6321.5822.9418.68
Book Value Per Share12.7216.9119.1827.9030.9659.79
Tangible Book Value Per Share6.3216.9119.1827.9030.9659.79
Full-Time Employees--6---
Price to Book Ratio0.190.230.310.400.480.19
Return on Assets-55.03-64.04-55.53-40.91-48.07-44.25
Return on Equity-68.21-72.12-64.21-46.34-53.99-49.58
Return on Invested Capital-21.30-13.69-30.53-9.90-12.16-6.54
Quick Ratio4.167.716.557.988.719.02
Current Ratio4.167.716.557.988.719.02

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.72-1.91-4.82-1.89-2.50-1.10
Depreciation--0.000.000.000.00
Other Funds (Non Cash)0.390.242.380.020.600.08
Funds from Operations-2.33-1.67-2.44-1.87-1.90-1.03
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.21-0.870.49-0.070.63-0.14
Cash from Operating Activities-2.13-2.54-1.95-1.94-1.27-1.17
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions-3.180.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments5.430.151.43-0.00-4.57-0.23
Purchase of Investments0.00-1.570.60-0.00-4.55-1.03
Sale Or Maturity of Investments5.431.720.820.00-0.010.80
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities2.240.151.43-0.00-4.57-0.23
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.200.001.190.296.041.51
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.200.001.190.296.041.51
Proceedsfrom Stock Options1.200.001.190.296.041.51
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.200.001.190.296.041.51
Net Change in Cash1.32-2.380.67-1.650.200.12
Free Cash Flow-2.13-2.54-1.95-1.94-1.27-1.17

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.82%0.0M1.0M24.36K
2026-10-150.74%0.0M1.0M59.38K
2026-09-301.38%0.0M1.0M60.91K
2026-09-151.10%0.0M1.0M63.30K
2026-08-140.46%0.0M1.0M92.94K
2026-07-311.83%0.0M1.0M96.07K
2026-07-15-0.0M-63.32K
2026-06-301.00%0.0M0.9M426.02K
2026-06-154.40%0.0M0.8M417.31K
2026-05-290.27%0.0M0.8M376.13K
2026-05-150.91%0.0M0.8M376.11K
2026-04-301.77%0.0M0.8M379.41K
2026-04-158.24%0.1M0.8M383.21K
2026-03-310.29%0.0M0.8M7.01K
2026-03-130.32%0.0M0.7M8.57K
2026-02-270.50%0.0M0.7M12.74K
2026-02-130.52%0.0M0.7M262.07K
2026-01-301.03%0.0M0.7M261.99K
2026-01-151.14%0.0M0.7M257.97K
2025-12-311.35%0.0M0.7M254.27K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-10SEC
2026-09-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-09SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-09-03EFFECTEffectiveness filing by commission orderSEC
2026-09-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-03SEC
2026-09-02POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-09-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-09-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-02SEC
2026-08-196-K/A2026-07-22SEC
2026-08-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-19SEC
2026-08-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-17SEC
2026-08-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-14SEC
2026-07-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-31SEC
2026-07-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-29SEC
2026-07-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-28SEC
2026-07-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-22SEC
2026-07-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-16SEC
2026-07-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-08SEC
2026-06-22424B3SEC
2026-06-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-22SEC
2026-06-08POS EXPost-effective amendment filed solely to add exhibits to a registration statementSEC
2026-06-08424B3SEC
2026-06-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-08SEC
2026-06-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-02SEC
2026-05-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-14SEC
2026-05-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-06SEC
2026-04-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-14SEC
2026-04-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-09SEC
2026-04-01EFFECTEffectiveness filing by commission orderSEC
2026-03-31POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
CITADEL ADVISORS LLC8.67%
HRT FINANCIAL LP4.20%
XTX Topco Ltd1.50%
TWO SIGMA SECURITIES, LLC1.10%
ROYAL BANK OF CANADA0.05%
MORGAN STANLEY0.01%
WELLS FARGO & COMPANY/MN0.00%
TSFG, LLC0.00%
Federation des caisses Desjardins du Quebec0.00%
JPMORGAN CHASE & CO0.00%

Funds

Fund% owned
Nomura Healthcare Fund0.17%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. EOCN. Cached 15 minutes. Terms

Some panels did not load: insider.